Palisade Bio (PALI) Total Liabilities (2010 - 2026)
Palisade Bio (PALI) reported Total Liabilities of $6.0 million for Q1 2026, up 108.22% year-over-year from $2.9 million in Q1 2025, and up 19.92% on a QoQ basis from $5.0 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Total Liabilities data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Total Liabilities rose 108.22% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 108.22% YoY) and the FY2025 annual result came in at $5.0 million, up 46.52% from the prior year.
- Total Liabilities improved to $6.0 million in Q1 2026 per PALI's latest filing, from $5.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $6.0 million in Q1 2026 and bottomed at $1.5 million in Q1 2023.
- The 5-year median for Total Liabilities is $3.3 million (2022), against an average of $3.4 million.
- Peak annual rise in Total Liabilities reached 199.97% in 2022, while the deepest fall reached 85.26% in 2022.
- Tracing PALI's Total Liabilities over 5 years: stood at $3.3 million in 2022, then fell by 16.6% to $2.7 million in 2023, then advanced by 23.69% to $3.4 million in 2024, then surged by 46.52% to $5.0 million in 2025, then advanced by 19.92% to $6.0 million in 2026.
- Per Business Quant, the three latest PALI Total Liabilities figures stand at $6.0 million (Q1 2026), $5.0 million (Q4 2025), and $3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 5.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.95 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 3.84 Mn |
| Jun 30, 2022 | 3.60 Mn |
| Mar 31, 2022 | 3.56 Mn |
| Dec 31, 2021 | 5.15 Mn |
| Sep 30, 2021 | 12.35 Mn |
| Jun 30, 2021 | 24.39 Mn |
| Mar 31, 2021 | 1.19 Mn |
| Dec 31, 2020 | 10.12 Mn |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 867,369.00 |
| Mar 31, 2020 | 1.38 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Sep 30, 2019 | 1.90 Mn |
| Jun 30, 2019 | 1.56 Mn |
| Mar 31, 2019 | 2.13 Mn |
| Dec 31, 2018 | 1.63 Mn |
| Sep 30, 2018 | 3.24 Mn |
| Jun 30, 2018 | 3.06 Mn |
| Mar 31, 2018 | 4.94 Mn |
| Dec 31, 2017 | 5.37 Mn |
| Sep 30, 2017 | 4.62 Mn |
| Jun 30, 2017 | 5.58 Mn |
| Mar 31, 2017 | 8.95 Mn |
| Dec 31, 2016 | 11.27 Mn |
| Sep 30, 2016 | 12.24 Mn |
| Jun 30, 2016 | 12.46 Mn |
| Mar 31, 2016 | 10.37 Mn |
| Dec 31, 2015 | 9.98 Mn |
| Sep 30, 2015 | 12.24 Mn |
| Jun 30, 2015 | 11.83 Mn |
| Mar 31, 2015 | 11.44 Mn |
| Dec 31, 2014 | 12.12 Mn |
| Sep 30, 2014 | 8.54 Mn |
| Jun 30, 2014 | 8.60 Mn |
| Mar 31, 2014 | 9.03 Mn |
| Dec 31, 2013 | 11.00 Mn |
| Sep 30, 2013 | 10.90 Mn |
| Jun 30, 2013 | 9.43 Mn |
| Mar 31, 2013 | 9.72 Mn |
| Dec 31, 2012 | 1.78 Mn |
| Sep 30, 2012 | 2.14 Mn |
| Jun 30, 2012 | 1.47 Mn |
| Mar 31, 2012 | 2.31 Mn |
| Dec 31, 2011 | 2.43 Mn |
| Sep 30, 2011 | 1.99 Mn |
| Jun 30, 2011 | 1.15 Mn |
| Dec 31, 2010 | 2.74 Mn |